# OnCo record coherus (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/coherus/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "coherus" ;
  schema:name "Coherus BioSciences"@en ;
  schema:alternateName "Coherus BioSciences, Inc."@en, "Coherus Oncology"@en ;
  schema:description "Coherus is a Californian company that grew up on biosimilars and now holds the US rights to toripalimab, the anti-PD-1 antibody approved in 2023 for nasopharyngeal carcinoma, the first FDA approval for that cancer."@en ;
  schema:url <https://onco.cc/companies/coherus/>, <https://www.coherus.com/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.coherus.com/>, <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications> ;
  onco:tag "fda-oce-applicant" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/esophageal/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:drugs <https://onco.cc/drugs/toripalimab/> ;
  onco:trials <https://onco.cc/trials/nct06975293/> .